Adoptive Immunotherapy of Patients with Metastatic Renal Cell Cancer Using Lymphokine-Activated Killer Cells, lnterleukin-2 and Cyclophosphamide: Long-Term Results

1998 ◽  
Vol 5 (1) ◽  
pp. 16-21 ◽  
Author(s):  
Yoshihiko Tomita ◽  
Akiyoshi Katagiri ◽  
Kazuhide Saito ◽  
Tomoyuki Imai ◽  
Toshihiro Saito ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Adoptive Immunotherapy ◽  
Renal Cell ◽  
Cell Cancer ◽  
Long Term Results ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Metastatic Renal Cell Cancer

Long-term follow-up in patients with metastatic renal cell cancer not treated with IL-2

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4597-4597
Author(s):  
V. K. Chand ◽  
J. Sidloski ◽  
G. Clamon ◽  
R. J. Hohl
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer ◽  
Long Term Follow Up

scholarly journals Effect of Positive Surgical Margin on Survival After Partial Nephrectomy for Renal Cell Cancer: Long-term Results of a Single Center

2020 ◽  
Vol 7 (4) ◽  
pp. 316-324
Author(s):  
Mehmet Çağlar Çakıcı ◽  
Nihat Karakoyunlu ◽  
Alihan Kokurcan ◽  
Sercan Sarı ◽  
Fatih Sandıkçı ◽  
...  
Keyword(s):  
Partial Nephrectomy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Surgical Margin ◽  
Long Term Results ◽  
Positive Surgical Margin ◽  
Single Center

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

Sign in / Sign up

Export Citation Format

Share Document